Chhindwara, Madhya Pradesh — Health officials are investigating the potential link between cough syrup and a troubling rise in pediatric illnesses and deaths in India. A central team from the National Centre for Disease Control (NCDC) is currently evaluating samples in Chhindwara district, where reports have surfaced of children suffering from severe health issues after consuming specific cough medications.
The investigation intensified following the tragic death of a five-year-old boy in Sikar, Rajasthan. His condition deteriorated after consuming syrup provided through the state’s free medicine initiative. In a separate incident, a three-year-old in Bharatpur is seriously ill after using the same product. In Chhindwara, officials reported that six children have died over the last month from suspected kidney infections attributed to consuming similar syrups, prompting immediate action from local health authorities.
As part of the investigation, health officials are testing various samples, including water, entomological, and drug specimens, to rule out infectious diseases. However, the quality of the cough syrup has emerged as the primary concern. Two specific syrups, Coldrif and Nextro-DS, have already been banned in the district following alarming reports regarding their safety.
In Rajasthan, a two-year-old girl was admitted to a private hospital in critical condition after receiving the cough syrup at a government dispensary. Initially placed in the ICU, she has since been moved to a general ward as her condition improved. This case follows others reported in Bharatpur and Sikar, where multiple children similarly fell ill after taking the syrup. Notably, a doctor treating these children also experienced adverse effects after using the cough syrup.
Dr. Naresh Gunnade, the Acting Chief Medical and Health Officer in Chhindwara, noted that the first suspected case in his area was logged on August 24, with the first fatality reported on September 7. Symptoms among the affected children included high fever and difficulty urinating. In light of these incidents, local authorities have acted swiftly to suspend the use of the implicated syrups and implemented rigorous monitoring measures.
On September 28, district health officials raised alarms concerning specific batch numbers of the syrup produced by Kaysons Pharma—a Jaipur-based company. The Rajasthan Medical Services Corporation Limited (RMSCL) has since ceased the distribution of these batches and initiated an internal investigation involving a three-member committee. Officials indicated that over 133,000 patients have received the syrup since June, but emerging health issues have prompted a reevaluation of its safety.
Rajasthan Drug Controller Ajay Phatak confirmed the suspension of all supplies of Dextromethorphan Hydrobromide syrup across the state as health officials await test results. Initial assessments raise concerns about the syrup’s suitability for young children; all affected patients were under four years old. Experts have highlighted that the syrup is mainly intended for adult use, which raises serious questions about prescription practices within public health initiatives.
As investigations continue in both Rajasthan and Madhya Pradesh, health experts are urging parents against administering over-the-counter cough medicines to children without medical guidance. One pulmonologist from Jaipur cautioned, “Parents should consult a physician before giving any syrup or medication to children, especially those under five.”
The situation remains dynamic as local and state health authorities await laboratory results from testing and further evaluations from the investigative committee. In the meantime, the distribution and use of the implicated syrup batches remain strictly suspended as the integrity of public health schemes is scrutinized.